S9 Ep3: FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC
OncLive® On Air - A podcast by OncLive® On Air
Dr Armstrong discusses the FDA approval of olaparib plus abiraterone in patients with BRCA-mutated mCRPC, key efficacy and safety data from the PROpel trial, and where the field of prostate cancer research may be headed in the future.
